Top Markets
#1 Islamic Coin Islamic Coin +151.48%
#2 DOVU DOVU +48.44%
#3 Black Phoenix Black Phoenix +34.78%
#4 Velvet Velvet +31.18%
#5 Cross Cross +22.50%
#6 Akedo Akedo +15.95%
#7 DoubleZero DoubleZero +14.89%
#8 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.53%
#9 Fake World Assets Fake World Assets +10.34%
#10 Cap Cap +10.26%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Aequus Pharmaceuticals Inc. Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc.

AQS
Rank in Stocks #39473
Aequus Pharmaceuticals Inc. is a specialized Canadian pharmaceutical company... Aequus Pharmaceuticals Inc. is a specialized Canadian pharmaceutical company dedicated to advancing and commercializing therapeutic solutions. Its core operations span critical areas such as neurology, ophthalmology, and transplantation. The company currently markets a range of products, including Vistitan, an ophthalmic treatment designed to alleviate elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Another key offering is Tacrolimus IR, an immunosuppressant vital for both preventing and treating acute rejection in organ transplant recipients. Aequus also provides its Evolve line of dry eye products, which target various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness, alongside a preservative-free ophthalmic option. In its development pipeline, Aequus is progressing several innovative candidates. These include Topiramate XR and Oxcarbazepine XR, extended-release oral tablets aimed at epilepsy treatment; AQS1303, a transdermal formulation of pyridoxine/doxylamine developed to combat nausea and vomiting during pregnancy; and AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. To support its market reach and innovation, Aequus has forged strategic alliances. These include an agreement with Sandoz Canada, Inc. for the promotion of Vistitan; a partnership with Supernus Pharmaceuticals, Inc. for the marketing of its extended-release anti-epileptic drugs; and a collaboration with Medicom Healthcare Ltd. centered on preservative-free ophthalmic treatments. Established in 2013, Aequus Pharmaceuticals Inc. maintains its corporate headquarters in Vancouver, Canada.
Share Price
$0.00359455
Last synced: 2025-05-20
Market Cap
$476.76K
Change (1 day)
0.44%
Change (1 year)
0.00%
Country
CA
Trade Aequus Pharmaceuticals Inc. (AQS)

Category

Healthcare
Revenue for Aequus Pharmaceuticals Inc. (AQS)
Revenue in Aug 2026 TTM: 0
According to Aequus Pharmaceuticals Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Aequus Pharmaceuticals Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
 - -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
 - -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
 - -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
 - -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
 $6.61B -
IN